Nuclear expression of lysyl oxidase enzyme is an independent prognostic factor in rectal cancer patients
Metrics: PDF 1457 views | HTML 1863 views | ?
Na Liu1,2, Thomas R. Cox3, Weiyingqi Cui1, Gunnar Adell1, Birgitta Holmlund1, Jie Ping4, Ingvar Jarlsfelt5, Janine T. Erler3 and Xiao-Feng Sun1
1Department of Oncology and Department of Clinical and Experimental Medicine, Linköping University, SE-58185, Linköping, Sweden
2State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, 710032, Xi’an, China
3Biotech Research and Innovation Centre (BRIC), University of Copenhagen, DK-2200, Copenhagen, Denmark
4Shanghai Center for Bioinformation Technology, 201203, Shanghai, China
5Department of Pathology, Ryhov Hospital, SE-55111, Jönköping, Sweden
Xiao-Feng Sun, email: firstname.lastname@example.org
Keywords: lysyl oxidase, nuclear localisation, prognosis, rectal cancer patient
Received: February 20, 2016 Accepted: May 12, 2016 Published: May 26, 2016
Emerging evidence has implicated a pivotal role for lysyl oxidase (LOX) in cancer progression and metastasis. Whilst the majority of work has focused on the extracellular matrix cross-linking role of LOX, the exact function of intracellular LOX localisation remains unclear. In this study, we analysed the LOX expression patterns in the nuclei of rectal cancer patient samples and determined the clinical significance of this expression. Nuclear LOX expression was significantly increased in patient lymph node metastases compared to their primary tumours. High nuclear LOX expression in tumours was correlated with a high rate of distant metastasis and increased recurrence. Multivariable analysis showed that high nuclear LOX expression was also correlated with poor overall survival and disease free survival. Furthermore, we are the first to identify LOX enzyme isoforms (50 kDa and 32 kDa) within the nucleus of colon cancer cell lines by confocal microscopy and Western blot. Our results show a powerful link between nuclear LOX expression in tumours and patient survival, and offer a promising prognostic biomarker for rectal cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.